INCY
Price
$70.20
Change
-$0.29 (-0.41%)
Updated
Jul 25 closing price
Capitalization
13.59B
2 days until earnings call
SYRE
Price
$17.79
Change
+$0.19 (+1.08%)
Updated
Jul 25 closing price
Capitalization
1.07B
4 days until earnings call
Interact to see
Advertisement

INCY vs SYRE

Header iconINCY vs SYRE Comparison
Open Charts INCY vs SYREBanner chart's image
Incyte
Price$70.20
Change-$0.29 (-0.41%)
Volume$1.43M
Capitalization13.59B
Spyre Therapeutics
Price$17.79
Change+$0.19 (+1.08%)
Volume$841.4K
Capitalization1.07B
INCY vs SYRE Comparison Chart in %
Loading...
INCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INCY vs. SYRE commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCY is a Hold and SYRE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (INCY: $70.20 vs. SYRE: $17.79)
Brand notoriety: INCY: Notable vs. SYRE: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INCY: 79% vs. SYRE: 149%
Market capitalization -- INCY: $13.59B vs. SYRE: $1.07B
INCY [@Biotechnology] is valued at $13.59B. SYRE’s [@Biotechnology] market capitalization is $1.07B. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INCY’s FA Score shows that 1 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • INCY’s FA Score: 1 green, 4 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, INCY is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INCY’s TA Score shows that 4 TA indicator(s) are bullish while SYRE’s TA Score has 4 bullish TA indicator(s).

  • INCY’s TA Score: 4 bullish, 2 bearish.
  • SYRE’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, INCY is a better buy in the short-term than SYRE.

Price Growth

INCY (@Biotechnology) experienced а +3.45% price change this week, while SYRE (@Biotechnology) price change was +9.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.62%. For the same industry, the average monthly price growth was +17.39%, and the average quarterly price growth was +28.36%.

Reported Earning Dates

INCY is expected to report earnings on Nov 04, 2025.

SYRE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+7.62% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INCY($13.6B) has a higher market cap than SYRE($1.07B). INCY has higher P/E ratio than SYRE: INCY (351.00) vs SYRE (1.72). INCY YTD gains are higher at: 1.636 vs. SYRE (-23.582). INCY has higher annual earnings (EBITDA): 407M vs. SYRE (-214.36M). INCY has more cash in the bank: 2.41B vs. SYRE (565M). SYRE has less debt than INCY: SYRE (0) vs INCY (43.1M). INCY has higher revenues than SYRE: INCY (4.41B) vs SYRE (0).
INCYSYREINCY / SYRE
Capitalization13.6B1.07B1,266%
EBITDA407M-214.36M-190%
Gain YTD1.636-23.582-7%
P/E Ratio351.001.7220,459%
Revenue4.41B0-
Total Cash2.41B565M426%
Total Debt43.1M0-
FUNDAMENTALS RATINGS
INCY vs SYRE: Fundamental Ratings
INCY
SYRE
OUTLOOK RATING
1..100
6216
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
74
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8998
PRICE GROWTH RATING
1..100
5154
P/E GROWTH RATING
1..100
284
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SYRE's Valuation (74) in the Pharmaceuticals Major industry is in the same range as INCY (92) in the Biotechnology industry. This means that SYRE’s stock grew similarly to INCY’s over the last 12 months.

SYRE's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as INCY (100) in the Biotechnology industry. This means that SYRE’s stock grew similarly to INCY’s over the last 12 months.

INCY's SMR Rating (89) in the Biotechnology industry is in the same range as SYRE (98) in the Pharmaceuticals Major industry. This means that INCY’s stock grew similarly to SYRE’s over the last 12 months.

INCY's Price Growth Rating (51) in the Biotechnology industry is in the same range as SYRE (54) in the Pharmaceuticals Major industry. This means that INCY’s stock grew similarly to SYRE’s over the last 12 months.

INCY's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for SYRE (84) in the Pharmaceuticals Major industry. This means that INCY’s stock grew significantly faster than SYRE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INCYSYRE
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
55%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
57%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
63%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
59%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 4 days ago
60%
Bullish Trend 4 days ago
85%
Declines
ODDS (%)
Bearish Trend 2 days ago
61%
Bearish Trend 16 days ago
90%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
52%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
INCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ISHP40.751.01
+2.54%
First Trust S-Network Glb E-Com ETF
PBL29.920.14
+0.47%
PGIM Portfolio Ballast ETF
ZDEK24.800.04
+0.14%
Innovator Equity Defined Prt ETF -1YrDec
QQXT101.14-0.07
-0.07%
First Trust NASDAQ-100 ex-Tech Sect ETF
EOT16.12-0.14
-0.86%
EATON VANCE NATIONAL Municipal OPPORTUNITIES TRUST